Sorafenib (Nexavar)

Medicine at a glance

Sorafenib is an oral targeted cancer medicine. Nexavar is a verified brand; generic sorafenib products also exist. It interferes with several signals that support cancer growth and the formation of blood vessels feeding a tumour. It is normally taken every day, usually twice daily, with regular checks for side effects and cancer control.

The usual full adult dose is two 200 mg tablets twice daily, but your prescription may be lower or use a different schedule. Skin soreness on the hands or feet, diarrhoea, fatigue, hair changes and high blood pressure are important practical concerns. Early reporting can allow treatment changes before symptoms become disabling.

This guide supports your treatment discussion. Food and missed-dose instructions differ between US and European product information; follow the leaflet and written plan for your actual supply. Overseas brand verification does not establish local availability.

What sorafenib is and how it works

Sorafenib is a multikinase inhibitor. Kinases are proteins that pass messages within cells. Sorafenib inhibits several pathways, including RAF signalling involved in cell growth and VEGF-related signalling involved in new blood-vessel development. This can interfere with both cancer-cell activity and the tumour's blood supply.

It is different from conventional chemotherapy and checkpoint immunotherapy. The word targeted does not mean harmless: normal blood vessels, skin, the bowel and other tissues can also be affected. Side effects are therefore assessed alongside benefit, and a lower dose may be a deliberate part of ongoing care. There is no guarantee of response or a single expected treatment duration for every person.

How the team decides whether it is suitable

The oncologist considers your diagnosis, disease activity, previous treatments, other options, symptoms and general health. Sorafenib does not have one universal required mutation test across all its treatment settings. Tests may still be needed to confirm the diagnosis or guide the overall cancer plan; they are not all sorafenib eligibility tests.

Liver reserve is especially important when there is underlying liver disease. Severe liver impairment and dialysis have limited evidence. A previous severe allergy to sorafenib or an ingredient is a contraindication. The safety and effectiveness of routine paediatric treatment are not established.

The team also checks the whole proposed regimen. Some chemotherapy combinations with sorafenib have caused harm in particular settings; the US label specifically contraindicates its combination with carboplatin and paclitaxel in squamous lung cancer. Do not add it to another person's treatment or assume that combining cancer medicines is automatically better.

Before treatment starts

Tell the team about heart disease, a recent heart attack, high blood pressure, abnormal rhythms, fainting, previous aneurysm or artery dissection, bleeding and blood-thinning medicines. Explain any kidney or liver problems, diabetes, thyroid treatment, low calcium, troublesome skin conditions or planned surgery and dental procedures. Report previous radiotherapy and any pregnancy possibility.

Baseline assessment usually includes blood pressure, blood counts, liver and kidney function, and electrolytes such as calcium, potassium and magnesium. Thyroid tests are particularly important when thyroid hormone suppression is part of your cancer treatment. An ECG is considered according to heart history, medicines and electrolyte risk; it is not automatically the same schedule for every patient. Pregnancy testing is required when relevant.

Discuss existing painful calluses, cracks or pressure areas on your feet before starting. The team can advise safe skin care or podiatry. Have your pharmacist review prescription medicines, shop-bought products, herbal remedies and supplements. Obtain your hospital's urgent contact details and clear instructions for bowel symptoms, skin changes and missed doses.

How treatment is taken

Dose and schedule

A usual full adult starting dose is 400 mg twice daily, using 200 mg tablets. Take doses consistently at the times prescribed. There is usually no planned week off. Treatment continues while it is beneficial and tolerable, with holds or dose reductions when necessary.

Dose reduction patterns differ by treatment setting. A prescription may use unequal morning and evening doses or a once-daily schedule. Check the milligrams, tablet count and days carefully after a change; do not try to reproduce someone else's reduction plan. A blister pack's printed days do not override your prescription.

Food instructions

US Nexavar guidance is to take each dose on an empty stomach, at least one hour before or two hours after food. European guidance permits taking it without food or with a low- or moderate-fat meal. If eating a high-fat meal, the European instruction is also at least one hour before or two hours afterwards. A high-fat meal can lower absorption.

These are regional instructions, not a reason to alternate between methods. Agree a workable daily routine with the pharmacist and use the same product-specific plan. If you cannot eat normally or meal times change during illness, obtain advice rather than missing multiple doses or taking extra tablets.

Missed or vomited doses

US instructions say to skip a forgotten dose and take the next one at the normal time. The European leaflet says to take it when remembered unless the next dose is nearly due, in which case skip it. There is no single hour-based cut-off in that European wording; ask for a practical plan if needed. Never double a dose.

If you vomit just after taking sorafenib, do not take replacement tablets. Take the next scheduled dose normally. Persistent vomiting, inability to drink or repeated missed doses needs advice from the team.

Swallowing storage and disposal

Swallow tablets whole with water. Do not crush, chew or prepare a liquid yourself. Tell the pharmacist before starting if swallowing is difficult or a feeding tube is used; the reviewed Nexavar product information does not provide a routine home dispersion or tube method.

Keep tablets in labelled packaging, away from children, heat and damp. US information specifies 20–25°C (68–77°F) in a dry place, with limited permitted temperature excursions; European information says not above 25°C (77°F). Follow your pack's instructions. Return unused or expired medicine to the pharmacy. If you accidentally take too much, seek medical advice immediately, even if you feel well.

Monitoring and checking whether treatment is working

Blood pressure is monitored closely because it may rise early without obvious symptoms. US guidance specifies weekly checks during the first six weeks and periodically afterwards; European guidance calls for regular monitoring. If asked to check at home, use the agreed technique and report readings outside your personal limits.

Blood tests assess liver function, kidney function, blood counts and electrolytes. Fluid balance needs particular attention with diarrhoea or kidney risk. Patients with diabetes need regular glucose checks because sorafenib can lower blood sugar, sometimes substantially.

When thyroid-stimulating hormone, or TSH, suppression is part of differentiated thyroid cancer care, sorafenib may make the existing replacement plan insufficient. US guidance checks TSH monthly; the European label calls for close monitoring. Calcium also needs particular attention in this setting, especially after parathyroid problems. Do not change thyroid or calcium treatment yourself.

ECGs and electrolyte checks are used when rhythm risk is increased. Warfarin users need additional attention to INR, the test that guides its anticoagulant effect. Scans and clinical assessments show whether cancer is controlled. Keep a symptom and dose record; a side-effect diary is useful but cannot replace laboratory tests or imaging.

Common side effects and practical management

Hand foot skin reaction

The palms and soles may become tender, red or darker, swollen, blistered or thickened, often at pressure points. This frequently starts during the first six weeks. It can affect walking, cooking, fastening buttons or using tools. Report early soreness rather than waiting until normal activities are impossible.

Use the skin-care products recommended by your team, comfortable footwear and measures that reduce rubbing and pressure. Avoid heat or activities that aggravate sore areas. Do not cut away calluses or burst blisters yourself. Painful or function-limiting symptoms may require prescribed topical treatment, a pause or a lower dose. The severity and recurrence guide the decision; continuing through severe pain is not necessary to prove commitment to treatment.

Diarrhoea and digestive symptoms

Diarrhoea is common and can cause dehydration and electrolyte loss. Use the agreed antidiarrhoeal plan and drink within any fluid restriction you have been given. Contact the team if stools are frequent or persistent, symptoms are worsening, or you have dizziness, reduced urine, fever or difficulty drinking. Blood in stools or severe abdominal pain requires urgent assessment.

Nausea, vomiting, reduced appetite and weight loss can affect nutrition. Take prescribed anti-sickness medicines and discuss smaller meals or dietetic support. Report painful swallowing, mouth sores or symptoms that make it difficult to eat. Do not add supplements or herbal appetite remedies without a medicine review.

Rash hair changes and mouth care

Dryness, itching and rash may need moisturisers or prescribed creams. Protect exposed skin from the sun. Report a new persistent growth, ulcer or changing skin lesion: some skin cancers and keratoacanthomas have been reported. A painful widespread rash with blisters or mucosal sores is a different problem and needs immediate assessment.

Hair may thin or be lost in patches. The amount varies; complete hair loss is less usual, and regrowth may occur after treatment. Mouth dryness, soreness or altered taste can also occur. Gentle cleaning and prompt treatment of painful sores can help preserve eating and drinking.

Fatigue pain and blood counts

Tiredness, aches and headache can affect daily activities. Alternate rest with manageable activity and ask for assessment if fatigue increases. Low red cells, thyroid changes, dehydration and poor nutrition may contribute. Check painkillers first, particularly anti-inflammatory tablets, because of bleeding and kidney risks.

Blood counts may fall and infection can occur. Report fever, shaking chills, cough or painful urination promptly. Easy bruising and bleeding need advice even if the platelet count was recently normal. Persistent low mood or sleep problems also deserve support.

Important side effects

Blood pressure heart and arterial problems

Severe hypertension, reduced blood supply to the heart, heart attack and heart failure can occur. Chest pain, severe breathlessness, collapse or a severe headache with confusion is an emergency. Report new ankle swelling, difficulty breathing when lying flat or palpitations promptly. Treatment may need interruption or permanent stopping according to the event.

Sorafenib can prolong the QT interval, the heart's electrical reset time. Salt disturbances and other medicines can increase the risk of dangerous rhythms. US information advises avoiding it in congenital long-QT syndrome. Fainting or a fast, slow or irregular heartbeat needs urgent assessment.

Arterial aneurysm, dissection or rupture has been reported with medicines affecting VEGF signalling, including sorafenib. An aneurysm is a weakened, enlarged artery; dissection is a tear in its wall. Sudden severe chest, back or abdominal pain requires emergency help. Controlling blood pressure and disclosing a previous aneurysm are important.

Bleeding and bowel perforation

Contact the team for unusual bruising, repeated nosebleeds, blood in urine or heavier-than-usual vaginal bleeding. Coughing or vomiting blood, black tarry stools, uncontrolled bleeding or sudden neurological changes require emergency assessment. Bleeding may require permanent stopping; US instructions require this for at least moderate bleeding needing medical intervention. The team assesses severity.

A hole in the bowel wall, called perforation, is an uncommon but serious complication. Sudden or severe abdominal pain, tenderness, fever or persistent vomiting needs urgent hospital assessment. Confirmed perforation requires permanently stopping sorafenib; it is not treated by simply adding an antidiarrhoeal.

Liver injury and altered brain function

Sorafenib can cause serious liver inflammation. Seek immediate advice for jaundice, dark urine, upper abdominal pain, increasing abdominal swelling, marked nausea or unusual bleeding. Significant liver-test abnormalities without another explanation require stopping treatment under the label's criteria. Existing liver disease makes careful interpretation particularly important.

New confusion, unusual behaviour, profound sleepiness, seizures or visual changes must not be dismissed as ordinary fatigue. Reported neurological conditions include encephalopathy, meaning impaired brain function, and posterior reversible encephalopathy syndrome, which involves brain swelling. Severe symptoms require emergency assessment; tests determine the cause and whether sorafenib must be stopped.

Severe skin or allergic reactions

Stop taking sorafenib and seek emergency assessment for a spreading painful rash, blistering, peeling, or sores affecting the eyes, mouth or genitals. Stevens–Johnson syndrome and toxic epidermal necrolysis can be life-threatening. They are different from a mild rash or local hand–foot reaction; US guidance stops treatment when either severe syndrome is suspected. Swelling of the tongue or throat or difficulty breathing may indicate an allergic emergency.

Low blood sugar and kidney or muscle problems

Low glucose may cause sweating, shaking, hunger, palpitations, dizziness or confusion. Follow your existing hypoglycaemia plan if you are awake and can swallow, and contact the team promptly. Loss of consciousness or a seizure is an emergency: give nothing by mouth. European guidance requires temporary interruption for symptomatic hypoglycaemia and review of diabetes medicines.

Kidney injury, heavy protein loss in urine and severe muscle breakdown have been reported. New swelling, very little urine, dark urine with marked muscle pain or weakness, or unexplained bruising and neurological symptoms needs urgent assessment. The US label also records thrombotic microangiopathy, a condition affecting small blood vessels that can damage blood cells and kidneys. These symptoms have several possible causes and require tests.

Lung inflammation and tumour lysis

New cough, fever or breathlessness may indicate infection, heart problems or drug-related lung inflammation. Contact the team urgently; severe breathlessness is an emergency. Do not assume the cancer is the only possible explanation.

Tumour lysis syndrome has been reported, including fatal cases. Rapid breakdown of cancer cells can disturb electrolytes and kidney function. Higher-risk patients need close monitoring and sometimes preventive hydration. Reduced urine, weakness, cramps, palpitations, vomiting or confusion needs urgent advice; seizures or collapse require emergency care.

Other medicines supplements and vaccinations

Some medicines reduce sorafenib exposure, potentially reducing its effect. Strong enzyme inducers include rifampicin and certain seizure medicines; St John's wort is also important. US information advises avoiding neomycin because it can reduce absorption through changes in gut bacteria. Other antibiotics still need review, but do not stop an antibiotic prescribed for an infection without advice.

Warfarin requires INR and bleeding monitoring. US guidance advises avoiding medicines known to prolong QT, including some heart, antibiotic and anti-sickness drugs; European guidance advises caution and monitoring. Sorafenib can interact with other cancer treatments and transport-related medicines such as digoxin. Give every prescriber your current list.

A blanket ban on all CYP3A inhibitors or all acid-suppressing medicines is not appropriate for sorafenib. Studies with ketoconazole and omeprazole did not show the clinically significant exposure changes seen with some other targeted medicines. The pharmacist should still assess your individual combination rather than borrowing another drug's timing rules.

Vaccination timing depends on immune function and accompanying treatment. Discuss flu, COVID-19 and travel vaccines; do not arrange a live vaccine without the team's advice. A fixed post-treatment live-vaccine interval should not be assumed for every patient.

Everyday life during treatment

Adapt work and activity to energy levels and hand or foot soreness. Comfortable shoes and modified tasks may help; report symptoms before they threaten mobility or independence. Avoid driving when dizzy, weak, confused or otherwise impaired. Plan travel around tests, medicine supplies and access to urgent care.

Sorafenib may impair wound healing. US guidance requires a hold of at least ten days before elective surgery and no treatment for at least two weeks after major surgery and until healing is adequate. European guidance advises interruption for major surgery and bases restart on clinical assessment of healing without prescribing the same fixed interval. Agree dates with the treating team.

Tell the dentist before procedures and report persistent jaw pain, exposed bone or a socket that does not heal; jaw osteonecrosis has been reported in US postmarketing information. Maintain oral hygiene, discuss alcohol in the context of liver health, and ask for help with nutrition, intimacy or emotional strain when needed.

Fertility contraception pregnancy and breastfeeding

Sorafenib can harm an unborn baby. Pregnancy status is checked before treatment when relevant. US guidance requires effective contraception for patients who could become pregnant during treatment and for six months after the last dose. Male patients with a partner who could become pregnant, or a pregnant partner, need effective contraceptive precautions during treatment and for three months afterwards; agree suitable barrier precautions for a pregnant partner with the team.

European information requires effective contraception during treatment but does not specify the same fixed post-treatment intervals. Obtain written end dates from your team rather than assuming that precautions end with the final tablet. Report any possible pregnancy promptly. Other treatments may require longer restrictions.

Do not breastfeed during treatment. US guidance continues this restriction for two weeks after the last dose; the European label does not supply a fixed post-treatment interval. Animal findings suggest potential fertility harm, including male effects highlighted in US information and male and female effects in European information. Human risk is uncertain. Discuss fertility preservation before starting when feasible.

After treatment finishes

Keep follow-up appointments and blood tests until the team confirms what can stop. Continue blood-pressure, diabetes and thyroid medicines as directed; their doses may need reassessment when sorafenib is withdrawn. Do not assume they should all stop on the same day.

Report persistent skin injury, bleeding, jaundice, breathlessness or neurological symptoms even after the final dose. Follow the agreed contraception and breastfeeding dates. If treatment was paused for an operation or toxicity, obtain explicit restart instructions before using remaining tablets. Return unwanted supplies safely.

Frequently asked questions